Hoa Tran

Hoa Tran

Auto-generated profile, based on publicly available information

Hoa Tran

Department of Internal Medicine, School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2022 in American Journal of Case Reports
Verified
Journal Article
Open access
HTHoa Tran
Hoa Tran
HVHoang Vu Vu
Hoang Vu Vu
TPToan Thanh Phan
Toan Thanh Phan
KNKhang Duong Nguyen
Khang Duong Nguyen
BTBinh Quang Truong
Binh Quang Truong
Unusual clinical course Since the initial COVID-19 cases in 2019, the pandemic has expanded globally. Clinical data showed that dexamethasone treatment at a dose of 6 mg daily for up to 10 days in hospitalized patients with COVID-19 who were receiving respiratory support decreased 28-day mortality in COVID-19 patients. Recent reports, on the other hand, have indicated that both steroid resistance and rebound events occur. We report a case of rebound inflammation after the termination of dexamethasone medication in a 38-year-old man with severe COVID-19 pneumonia, which improved after the reintroduction of dexamethasone. A 38-year-old male patient with no past medical history of note presented with new onset of dyspnea. He was subsequently diagnosed with severe coronavirus disease 2019 (COVID-19). Initially, the patient was clinically improved following a 3-day course of 16 mg of dexamethasone daily. Shortly after discontinuing corticosteroids, the patient’s clinical condition deteriorated, necessitating increased oxygen support. Following the rein-troduction of corticosteroids, the patient gradually improved and responded favorably in terms of respiratory function, symptoms, and imaging, after which he was successfully discharged. This case exemplifies the previously observed rebound effects of discontinuing dexamethasone medication in individuals with severe COVID-19 pneumonia. The timing and length of dexamethasone medication should be tailored to the individual patient. In addition, monitoring lung function should be part of the gradual withdrawal of dexamethasone to avoid rebound lung inflammation and the long-term effects of increasing lung fibrosis.

30 April 2026 in BMC Medical Education
Verified
Journal Article
Open access
PDF file
Hai Nguyen Ngoc DangHai Nguyen Ngoc Dang
Hai Nguyen Ngoc Dang
TLThang Viet Luong
Thang Viet Luong
HVHoa Thi Ha Vo
Hoa Thi Ha Vo
LNLinh Thi Khanh Nguyen
Linh Thi Khanh Nguyen
TTTrung Nguyen Tran
Trung Nguyen Tran
TMThomas H. Marwick
Thomas H. Marwick
Artificial intelligence (AI) has emerged as a promising tool in medical education. It offers opportunities to enhance learning experiences, particularly th

16 June 2023 in Radiology Case Reports
Verified
Journal Article
Open access
BDBui The Dung
Bui The Dung
NHNguyen Thanh Hien
Nguyen Thanh Hien
NDNguyen Hoang Dinh
Nguyen Hoang Dinh
NDNgo Quoc Dat
Ngo Quoc Dat
KLKhoi Minh Le
Khoi Minh Le
Nguyen Minh DucNguyen Minh Duc
Nguyen Minh Duc
Primary pericardial mesothelioma is an extremely rare cancer with a short survival prognosis. Clinical symptoms are often atypical, and most patients are diagnosed after surgery or at autopsy. We report a case of a 35-year-old female patient with multiple serous membrane effusion for more than 1 year. The patient underwent pericardial, pleural, and peritoneal fluid drainage many times and underwent many laboratory tests to find the cause; however, there was no definitive diagnosis. She was admitted to the hospital because of shortness of breath, cough, and sputum for 5 days. She underwent extensive pericardiectomy to resolve the dyspnea and pericardial surgery to find the cause of the multiple serous membrane effusion. After surgery, her dyspnea was relieved, and the serous effusion gradually decreased.

31 March 2024 in MedPharmRes
Verified
Journal Article
Open access
PDF file
HVHoang Vu Vu
Hoang Vu Vu
TNThanh Cong Nguyen
Thanh Cong Nguyen
BNBinh Thi Hai Nguyen
Binh Thi Hai Nguyen
HTHoa Tran
Hoa Tran
BTBinh Quang Truong
Binh Quang Truong
MedPharmRes is owned by the University of Medicine and Pharmacy at Ho Chi Minh City and published under Open Access arrangement. MedPharmRes publishes quarterly and covers all fields in medicine, public health, epidemiology, and pharmacy, including drug synthesis and delivery and health and medical education research, in an attempt to bridge the gaps between healthcare and clinical specialization. The journal’s publication criteria are based on the accuracy of the research methodology and high ethical standards.

30 November 2023 in Biomedical Research and Therapy
Verified
Journal Article
Open access
PDF file
BDBui The Dung
Bui The Dung
TATran-Thi Xuan Anh
Tran-Thi Xuan Anh
THTran Hoa
Tran Hoa
Nguyen Minh DucNguyen Minh Duc
Nguyen Minh Duc
This case report highlights the successful management of a patient with light chain amyloidosis and New York Heart Association (NYHA) functional class IV heart failure who was ineligible for an autologous stem cell transplant (ASCT). They were managed with an oral melphalan and dexamethasone regimen in addition to standard heart failure treatment according to European Society of Cardiology-American Heart Association guidelines. They responded well to treatment, showing symptom improvement and the ability to function at the NYHA class II level. They were closely monitored throughout treatment, with regular testing for infective screening, systemic biochemical workup, echocardiography, and monitoring of N-terminal pro-B-type natriuretic peptide (NTproBNP) and troponin T levels. After 24 cycles of high-dose oral melphalan and dexamethasone chemotherapy, the patient could discontinue treatment and continue follow-up monitoring. The most recent workup showed significantly improved cardiac function, with decreased left ventricular wall thickness, improved diastolic function and strain, and decreased NT-proBNP level. This case report demonstrates the importance of considering alternative treatment options for patients ineligible for ASCT due to advanced heart involvement. It also highlights the potential benefits of an oral melphalan and dexamethasone regimen combined with standard heart failure treatment in improving clinical outcomes in these patients.

6 November 2025 in Health Science Reports
Verified
Journal Article
Open access
TTThanh Huong Truong
Thanh Huong Truong
HVHoang Anh Vu
Hoang Anh Vu
VHVan Sy Hoang
Van Sy Hoang
NNNgoc Quang Nguyen
Ngoc Quang Nguyen
HTHoa Tran
Hoa Tran
QTQuang Binh Truong
Quang Binh Truong
Background and Aims: Lipoprotein(a) (Lp[a]) is an independent cardiovascular risk factor. Although current guidelines recommend Lp(a) testing, physicians are seldom screened, even though they remain at risk and often overlook their own health. In Vietnam, data on Lp(a) remain unclear. To address this, the Vietnam Atherosclerosis Society launched a pilot study to assess elevated Lp(a) among Vietnamese cardiologists, aiming to generate initial data, encourage physician screening, and raise medical and public awareness. Methods: A cross‐sectional study was conducted at the 2024 Vietnam Atherosclerosis Society Congress, inviting 800 cardiologists. After exclusions, 165 without cardiovascular disease were analyzed. Demographic, biochemical, and lipid profiles were collected, and Lp(a) was measured using the Tina‐quant Lp(a) Gen 2 assay. Results: Elevated Lp(a) levels (≥ 125 nmol/L) were observed in 12.12% of the participants. There were no significant differences in median age ( p = 0.488) or sex distribution ( p = 0.328) between participants with and without elevated Lp(a). Lp(a) levels were not correlated with other lipid parameters, body mass index, or age. No significant difference in Lp(a) levels was observed between statin users and nonstatin users. Among participants who achieved LDL‐C and non‐HDL‐C treatment targets, 8% still presented elevated Lp(a) levels. Conclusion: At the Vietnam Atherosclerosis Society Congress, elevated Lp(a) levels were detected in several cardiologists without prior cardiovascular disease, including those with well‐controlled lipid profiles according to current guideline targets.